Isabl for Pharma

About Isabi

Isabl is a private, pre-revenue diagnostics company developing a comprehensive whole-genome and transcriptome sequencing (WGTS) platform for cancer. Its proprietary Isabl GxT technology, which has received FDA Breakthrough Device Designation, aims to replace limited gene panels by analyzing the entire tumor genome and transcriptome to identify all classes of clinically relevant biomarkers from a single biopsy. Spun out from Memorial Sloan Kettering Cancer Center in 2020, the company is backed by notable investors including Two Sigma Ventures and Y Combinator and is preparing for a Research Use Only (RUO) release of its test in 2024 while pursuing clinical partnerships.

Therapeutic Areas